Juan
Turnes Vázquez
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (12)
2024
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211
2023
-
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737
2021
-
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review
Scientific Reports, Vol. 11, Núm. 1
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test
World Journal of Gastroenterology, Vol. 26, Núm. 1, pp. 70-85
2019
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
2017
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4
Liver International, Vol. 37, Núm. 12, pp. 1823-1832
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2016
-
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients with Cirrhosis
Gastroenterology, Vol. 150, Núm. 5, pp. 1160-1170.e3
2015
-
Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery
Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153